A detailed history of Marshall Wace, LLP transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 44,483 shares of ANIX stock, worth $139,676. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,483
Holding current value
$139,676
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.21 - $3.48 $98,307 - $154,800
44,483 New
44,483 $140,000
Q1 2024

May 15, 2024

BUY
$3.08 - $5.02 $48,346 - $78,798
15,697 Added 147.04%
26,372 $82,000
Q4 2023

Feb 14, 2024

BUY
$2.85 - $4.19 $30,423 - $44,728
10,675 New
10,675 $41,000
Q2 2022

Aug 15, 2022

SELL
$2.55 - $4.1 $73,753 - $118,584
-28,923 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.5 - $3.42 $32,625 - $44,631
-13,050 Reduced 31.09%
28,923 $80,000
Q3 2021

Nov 15, 2021

BUY
$3.57 - $5.6 $149,843 - $235,048
41,973 New
41,973 $200,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $96.3M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.